Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
30.81
-0.37 (-1.19%)
At close: Jul 24, 2026, 4:00 PM EDT
30.91
+0.10 (0.31%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Teva Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3,741 | 3,556 | 3,300 | 3,226 | 2,801 | 2,165 |
Cash & Short-Term Investments | 3,741 | 3,556 | 3,300 | 3,226 | 2,801 | 2,165 |
Cash Growth | 120.45% | 7.76% | 2.29% | 15.17% | 29.38% | -0.55% |
Accounts Receivable | 3,393 | 3,709 | 3,059 | 3,408 | 3,696 | 4,529 |
Inventory | 3,176 | 3,179 | 3,007 | 4,021 | 3,833 | 3,818 |
Other Current Assets | 3,399 | 3,503 | 3,186 | 1,829 | 1,721 | 2,059 |
Total Current Assets | 13,710 | 13,946 | 12,552 | 12,485 | 12,051 | 12,573 |
Net Property, Plant & Equipment | 4,333 | 4,425 | 4,948 | 6,147 | 6,158 | 6,477 |
Other Intangible Assets | 3,609 | 3,781 | 4,418 | 5,387 | 6,270 | 7,466 |
Goodwill | 15,822 | 16,000 | 15,147 | 17,177 | 17,633 | 20,040 |
Other Long-Term Assets | 2,567 | 2,596 | 2,261 | 2,282 | 1,899 | 1,111 |
Total Assets | 40,040 | 40,748 | 39,326 | 43,479 | 44,011 | 47,666 |
Accounts Payable | 2,596 | 2,531 | 2,203 | 2,602 | 1,887 | 1,686 |
Accrued Expenses | 6,878 | 7,569 | 7,094 | 6,917 | 6,467 | 7,012 |
Short-Term Debt | 2,612 | 1,820 | 1,781 | 1,672 | 2,109 | 1,426 |
Other Current Liabilities | 1,445 | 1,536 | 1,718 | 1,057 | 1,005 | 903 |
Total Current Liabilities | 13,532 | 13,456 | 12,796 | 12,247 | 11,469 | 11,027 |
Long-Term Debt | 14,015 | 14,986 | 16,002 | 18,161 | 19,103 | 21,617 |
Long-Term Leases | 280 | 288 | 296 | 320 | 349 | 416 |
Other Long-Term Liabilities | 3,982 | 4,104 | 4,511 | 4,625 | 4,493 | 3,362 |
Total Long-Term Liabilities | 18,277 | 19,379 | 20,809 | 23,106 | 23,944 | 25,395 |
Total Liabilities | 31,809 | 32,834 | 33,605 | 35,353 | 35,413 | 36,422 |
Common Stock | 59 | 58 | - | 57 | 57 | 57 |
Treasury Stock | -4,128 | -4,128 | - | -4,128 | -4,128 | -4,128 |
Additional Paid-in Capital | 28,203 | 28,133 | - | 27,807 | 27,688 | 27,561 |
Accumulated Other Comprehensive Income | -2,512 | -2,391 | - | -2,697 | -2,838 | -2,683 |
Retained Earnings | -13,394 | -13,762 | - | -13,534 | -12,975 | -10,529 |
Total Common Shareholders' Equity | 8,228 | 7,910 | 5,373 | 7,506 | 7,804 | 10,278 |
Minority Interest | 4 | 4 | 347 | 620 | 794 | 966 |
Shareholders' Equity | 8,232 | 7,914 | 5,720 | 8,126 | 8,598 | 11,244 |
Total Liabilities & Equity | 40,040 | 40,748 | 39,326 | 43,479 | 44,011 | 47,666 |
Total Debt | 16,907 | 17,094 | 18,079 | 20,153 | 21,561 | 23,459 |
Net Cash (Debt) | -13,166 | -13,538 | -14,779 | -16,927 | -18,760 | -21,294 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -11.26 | -11.64 | -13.07 | -15.13 | -16.90 | -19.24 |
Book Value | 8,228 | 7,910 | 5,373 | 7,506 | 7,804 | 10,278 |
Book Value Per Share | 7.04 | 6.80 | 4.75 | 6.71 | 7.03 | 9.28 |
Tangible Book Value | -11,203 | -11,871 | -14,192 | -15,058 | -16,099 | -17,228 |
Tangible Book Value Per Share | -9.58 | -10.21 | -12.55 | -13.46 | -14.50 | -15.56 |